J&J Can't Arbitrate Distributor's Claims In Remicade Row
A federal judge in Pennsylvania on Friday rejected Johnson & Johnson's bid to force direct purchasers of the immunosuppressant Remicade to arbitrate claims that it compelled insurers not to cover competing biosimilar versions of...To view the full article, register now.
Already a subscriber? Click here to view full article